Zuzanna Bober

Mrs. Zuzanna Bober

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
ZBZuzanna Bober
Zuzanna Bober
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher
David AebisherDavid Aebisher
David Aebisher
The application of dendrimeric constructs in medical diagnostics and therapeutics is increasing. Dendrimers have attracted attention due to their compact, spherical three-dimensional structures with surfaces that can be modified by the attachment of various drugs, hydrophilic or hydrophobic groups, or reporter molecules. In the literature, many modified dendrimer systems with various applications have been reported, including drug and gene delivery systems, biosensors, bioimaging contrast agents, tissue engineering, and therapeutic agents. Dendrimers are used for the delivery of macromolecules, miRNAs, siRNAs, and many other various biomedical applications, and they are ideal carriers for bioactive molecules. In addition, the conjugation of dendrimers with antibodies, proteins, and peptides allows for the design of vaccines with highly specific and predictable properties, and the role of dendrimers as carrier systems for vaccine antigens is increasing. In this work, we will focus on a review of the use of dendrimers in cancer diagnostics and therapy. Dendrimer-based nanosystems for drug delivery are commonly based on polyamidoamine dendrimers (PAMAM) that can be modified with drugs and contrast agents. Moreover, dendrimers can be successfully used as conjugates that deliver several substances simultaneously. The potential to develop dendrimers with multifunctional abilities has served as an impetus for the design of new molecular platforms for medical diagnostics and therapeutics.

1 January 2018 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
ZBZuzanna Bober
Zuzanna Bober
ASAgnieszka Ewa Stępień
Agnieszka Ewa Stępień
David AebisherDavid Aebisher
David Aebisher
ŁOŁukasz Ożóg
Łukasz Ożóg
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher

1 January 2018 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
ZBZuzanna Bober
Zuzanna Bober
ASAgnieszka Ewa Stępień
Agnieszka Ewa Stępień
David AebisherDavid Aebisher
David Aebisher
ŁOŁukasz Ożóg
Łukasz Ożóg
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher

1 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher
ZBZuzanna Bober
Zuzanna Bober
JZJolanta Zalejska-Fiolka
Jolanta Zalejska-Fiolka
David AebisherDavid Aebisher
David Aebisher
David AebisherDavid Aebisher
David Aebisher
The continuous development of magnetic resonance imaging broadens the range of applications to newer areas. Using MRI, we can not only visualize, but also track pharmaceutical substances and labeled cells in both in vivo and in vitro tests. 1H is widely used in the MRI method, which is determined by its high content in the human body. The potential of the MRI method makes it an excellent tool for imaging the morphology of the examined objects, and also enables registration of changes at the level of metabolism. There are several reports in the scientific publications on the use of clinical MRI for in vitro tracking. The use of multinuclear MRI has great potential for scientific research and clinical studies. Tuning MRI scanners to the Larmor frequency of a given nucleus, allows imaging without tissue background. Heavy nuclei are components of both drugs and contrast agents and molecular complexes. The implementation of hyperpolarization techniques allows for better MRI sensitivity. The aim of this review is to present the use of multinuclear MRI for investigations in drug delivery.

1 January 2017 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
ZBZuzanna Bober
Zuzanna Bober
David AebisherDavid Aebisher
David Aebisher
ŁOŁukasz Ożóg
Łukasz Ożóg
JTJacek Tabarkiewicz
Jacek Tabarkiewicz
PTPiotr Tutka
Piotr Tutka
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher

1 January 2017 in European Journal of Clinical and Experimental Medicine
Verified
Journal Article
Open access
ZBZuzanna Bober
Zuzanna Bober
David AebisherDavid Aebisher
David Aebisher
JTJacek Tabarkiewicz
Jacek Tabarkiewicz
WGWiesław Guz
Wiesław Guz
PTPiotr Tutka
Piotr Tutka
Dorota Bartusik-AebisherDorota Bartusik-Aebisher
Dorota Bartusik-Aebisher